Kindeva

Kindeva is a CDMO offering its partners integrated, end-to-end capabilities spanning formulation, product development, scale-up manufacturing and commercial manufacturing.

Its full-service innovation offering covers:

• Injectables (vials, pre-filled syringes, cartridges, autoinjectors)
• Inhalation (pMDIs, DPIs, connectivity, nasal delivery)
• Transdermal delivery (drug-in-adhesive systems, membrane systems, reservoir systems, gel patches)
• Intradermal delivery (microneedles based on solid and hollow microstructures)

Kindeva has locations in the US and the UK which are part of its global network of 10 manufacturing and R&D sites, including Annex 1-compliant state-of-the-art aseptic fill-finish capacity and next-generation sustainable inhalation propellant technology. It employs 2000 people.

The company was formed in 2020 when 3M’s Drug Delivery Systems (DDS) business was acquired by Altaris Capital Partners for US$650 million, and renamed Kindeva. 3M retains a 17% minority holding and Kindeva benefits from its 3M heritage comprising >50 years’ pharmaceutical development, commercialisation and contract manufacturing services experience across injectables, inhalation, nasal, transdermal and microneedles.